Bukwang Pharmaceutical Co

Name

Bukwang Pharmaceutical Co

Legal name

BUKWANG PHARM.CO.,LTD.

Website

https://bukwang.co.kr

Company type

Public

Founded year

1960

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Pharmaceutical manufacturing
• Prescription drugs
• CNS therapeutics
• Contract manufacturing
• Health functional foods

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Distribution channels4 records

Marketing channels3 records

Core offering

Bukwang Pharmaceutical develops, manufactures, and sells pharmaceutical products across prescription drugs, OTC medications, health functional foods, and household products, with R&D focused on CNS disorders (schizophrenia, bipolar disorder, Parkinson's disease). The company markets its products via medical representatives to hospitals, clinics, and pharmacies, sells consumer goods through a Naver Smart Store online storefront, co-promotes cardiovascular products with Servier, and provides contract manufacturing through its Korea Union Pharmaceutical subsidiary.

Product overview

Bukwang Pharmaceutical Co operates as a pharmaceutical company with a diversified portfolio spanning prescription drugs, OTC medications, health functional foods, and household products. The company's core R&D focus is on CNS (Central Nervous System) disorders, with key pipeline products including Latuda for schizophrenia/bipolar depression, JM-010 for Parkinson's disease dyskinesia, and CP-012 for morning akinesia in Parkinson's patients. In addition to its proprietary drug development through open innovation strategies, the company has expanded its cardiovascular portfolio through a co-promotion partnership with Servier covering 7 products including Asutile and Bastian brands. The company also manufactures and distributes a range of established pharmaceutical products across prescription, OTC, and health supplement categories.

Differentiator

Problem solved

Functional benefit

Products and services

• Latuda A prescription CNS drug for schizophrenia and bipolar depression that acts by blocking dopamine receptors in the brain; intended for hospital/clinic/pharmacy channel.
• JM-010 A pipeline prescription CNS drug repurposing already safety-proven compounds for the treatment of levodopa-induced dyskinesia in Parkinson's disease patients.
• CP-012 A pipeline prescription CNS product featuring a novel delayed-double pulsatile release levodopa/carbidopa oral formulation intended to treat morning akinesia in Parkinson's disease patients.
• Seokaredip Extended-Release Tablet 2mg (Melatonin) Prescription melatonin extended-release tablet for sleep regulation.
• Coritusal Escoff Soft Capsule Over-the-counter soft elastic capsule product.
• Legaron Capsule 140 Prescription capsule medication.
• SirinMed-F Toothpaste Household hygiene product.
• Tassenol Tablet 500mg (Acetaminophen) Over-the-counter acetaminophen 500mg pain reliever tablet.
• Feroba Extended-Release Tablet Prescription extended-release tablet formulation.
• Chiocta Side Tablet 200mg Prescription tablet 200mg.
• Dexside Tablet 480mg Prescription tablet 480mg.
• Araksil Granule Over-the-counter granule formulation.
• Addtamin Tablet Health functional food combining calcium and vitamin D as Korea's first 5-ingredient combination product for bone health supplementation.
• Asertil Tablet 4mg/8mg (Perindopril-t-butylamine) Prescription hypertension treatment co-promoted with Servier under a co-promotion agreement covering 7 cardiovascular products.
• Asertil Arginine Tablet 5mg/10mg (Perindopril Arginine) Prescription hypertension treatment using perindopril arginine base for improved stability, co-promoted with Servier.
• Asertil Plus Arginine Tablet (Perindopril Arginine + Indapamide) Combination prescription hypertension treatment combining perindopril arginine 5mg with indapamide 1.25mg and approximately 50% extended shelf life, co-promoted with Servier.
• Bastian Tablet / Bastian MR Extended-Release Capsule (Trimetazidine) Prescription anti-anginal medication (trimetazidine) for symptomatic treatment of stable angina patients who are inadequately controlled or intolerant to first-line therapy, co-promoted with Servier.
• Contract Manufacturing Services (Korea Union Pharmaceutical) Pharmaceutical contract manufacturing (CMO) services via Korea Union Pharmaceutical subsidiary, producing gastrointestinal drugs, thyroid and endocrine drugs, and additional categories for other pharmaceutical companies.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Korea Union PharmaceuticalcoreStrategic or Co-development Partner · 28 May 2026Bukwang Pharmaceutical acquired Korea Union Pharmaceutical through share purchase effective May 28, 2026, becoming its largest shareholder. Korea Union Pharmaceutical, which had been undergoing court rehabilitation proceedings, was acquired debt-free. The first contract-manufactured pharmaceutical product (gastrointestinal drug) was shipped on July 26. Additional products including thyroid and endocrine drugs are planned for manufacturing from August. Korea Union Pharmaceutical is actively seeking additional production contracts from other pharmaceutical companies.
• Dream CIS / AWScoreTechnology or Integration · 27 May 2026Bukwang Pharmaceutical signed a strategic MOU with Dream CIS and AWS for AI and organoid-based next-generation drug development. The partnership aims to build an integrated R&D platform covering preclinical to commercialization stages using AI and organoid technology.
• Servier (한국세르비에)coreGTM or Marketing Partner · 17 March 2026Bukwang Pharmaceutical entered into a strategic sales co-promotion agreement with French pharmaceutical company Servier for 7 cardiovascular products including Artel (perindopril) and Bastian (trimetazidine) product lines. Starting April 1, the companies conduct joint marketing activities with division of responsibilities based on hospital scale: Servier handles facilities with 300+ beds, joint responsibility for 100-299 beds, and Bukwang handles facilities under 100 beds.
• Servier (한국세르비에)coreGTM or Marketing PartnerCo-promotion agreement covering 7 cardiovascular products: Artel 4mg/8mg, Artel Arginine 5mg/10mg, Artel Plus Arginine, Bastian tablets, and Bastian MR sustained-release capsules. The agreement began April 1 with divided sales and marketing responsibilities based on hospital bed capacity.

Recent moves6 records

Expansion highlights6 records

Direct peers

• Hanmi Pharmaceutical: Major South Korea-based branded/innovator pharmaceutical company with a comparable portfolio spanning prescription drugs, OTC, and active CNS and metabolic development. Most directly comparable Korean peer given similar KOSPI-listed structure, scale, and R&D-driven strategy.
• Daewoong Pharmaceutical: Korean pharmaceutical company with a branded specialty portfolio and active CNS/neurology pipeline, plus consumer health and OTC extensions. Comparable in scale, listing status, and focus on innovative domestic CNS candidates plus international pipeline ambitions.
• Yuhan Corporation: One of Korea's largest established pharmaceutical companies with a broad prescription, OTC, and consumer health portfolio and growing specialty R&D. Closely comparable as a diversified Korean pharma incumbent with branded specialty development.
• Dong-A Pharmaceutical: Korean pharmaceutical company with a combined prescription, OTC, and consumer health portfolio including household-name brands. Directly comparable in operating model of branded pharma plus consumer health distribution within South Korea.
• JW Pharmaceutical: Mid-sized Korean specialty pharmaceutical company with branded prescription drugs and selective R&D focus. Comparable peer given similar KOSPI-listed domestic pharma model with specialty pharma emphasis.

Broad incumbents

• Otsuka Pharmaceutical: Major Japanese pharmaceutical group with a leading global CNS franchise (e.g., aripiprazole) and broad specialty pharma portfolio. Most relevant global incumbent in the schizophrenia/bipolar CNS space where Bukwang's Latuda-related pipeline competes.
• Sumitomo Pharma: Japanese-headquartered global pharmaceutical company with a strong CNS/neurology specialty focus (latuda-related franchise and Parkinson's programs). Direct comparator for Bukwang's CNS pipeline strategy and as a potential out-licensing counterpart.
• Lundbeck: Denmark-based specialty pharmaceutical company entirely focused on CNS disorders, including movement disorders like Parkinson's. Closely comparable therapeutic-area specialty focus despite being a global rather than Korean player.

Regional players

• GC Biopharma: Korean biopharmaceutical company with established prescription, vaccine, and blood product franchises. Comparable peer as a domestic Korean KOSPI-listed pharma with broader portfolio beyond pure CNS, useful for benchmarking capital allocation and pipeline diversity.
• Celltrion: Korean biopharmaceutical leader focused on biosimilars and novel biologics with significant domestic manufacturing and export reach. Comparable as a large-scale Korean pharma with manufacturing-driven growth and international commercialization potential.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bukwang Pharmaceutical Co